Pharma Mar, S.A.

OTC
PHMMF
Promotion
Rentabilité pendant six mois: +9.65%
Rendement des dividendes: 0.7456%
Secteur: Healthcare

96.69 $

0 $ 0%
34.26 $
105.6 $

Min./max. pendant un an

Calendrier de promotion Pharma Mar, S.A.

Calendrier prolongé Calendrier simple
Financial Markets by TradingView
Ajouter la comparaison
Ajouter la piste
Ajouter au portefeuille
Ajouter une notification des prix

Les principaux paramètres

Devise
usd
Div
0.7456
Dividende AO
0.6881
Industrie
Biotechnology
Isin
ES0169501022
La monnaie du rapport
usd
Secteur
Health Care
Site web
Système
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 7.81 1
P/BV 6.55 1
P/E 52.25 3
Efficacité
Nom Signification Grade
ROA 7.94 2
ROE 13.63 4
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement des dividendes 0.7456 1.88
DSI 0.9286 9.29
La croissance moyenne des dividendes 21.65 10
Devoir
Nom Signification Grade
Debt/EBITDA 2.4 6
Debt/Ratio 0.1461 10
Debt/Equity 0.6784 9
Pouls de croissance
Nom Signification Grade
Revenus, milliards, % -15.89 0
Ebitda, % -82.34 0
EPS, % -74.22 0
En savoir plus

Dividendes

En savoir plus

Prix

Prix Min. Max. Changement Changements dans l'industrie Changements dans l'index
Hier 96.69 $ 0 $ 0 $ 0 % 0 % 0 %
Semaine 91.22 $ 96.69 $ 96.69 $ +6 % 0 % 0 %
Mois 92.57 $ 91.22 $ 96.69 $ +4.46 % 0 % 0 %
3 mois 104.49 $ 91.22 $ 104.49 $ -7.46 % 0 % 0 %
Six mois 88.18 $ 80.91 $ 105.6 $ +9.65 % 0 % 0 %
Année 75 $ 34.26 $ 105.6 $ +28.93 % 0 % 0 %
3 ans 66.68 $ 26.85 $ 105.6 $ +45.02 % 0 % 0 %
5 ans 4.25 $ 26.85 $ 156 $ +2 175.15 % 0 % 0 %
10 ans 1.02 $ 1.02 $ 156 $ +9 479.8 % 0 % 0 %
Année à ce jour 105.6 $ 80.91 $ 105.6 $ -8.43 % 0 % 0 %

Propriétaires de base

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


La gestion de l'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Jose Maria Fernandez Sousa-Faro Ph.D. Founder, Executive Chairman, CEO & President 320.14k
Mr. Pedro Francisco Fernandez Puentes Executive Vice-Chairman 135.03k
Mr. Juan Carlos-Torres Carretero Founder N/A 1949 (76 années)
Ms. María Luisa de Francia Caballero Chief Financial Officer N/A
Mr. José Luis Moreno Martinez-Losa Head of Capital Markets & Investor Relations N/A
Mr. Juan Gomez Pulido General Counsel & Secretary of the Board of Directors N/A
Ms. Sandra Llamera Sanchez Global Compliance Head N/A
Ms. Lara Vadillo Communication Director N/A
Ms. Belén Sopesén Veramendi Ph.D. Director of Corporate Development N/A
Mr. Luis Rupérez Cuenca Director of Human Resources & IT N/A

Informations sur l'entreprise

Adresse: Spain, Madrid, Avenida de los Reyes. 1 - Ouvert sur google cards, Cartes yandex ouvertes
Site web: https://www.pharmamar.com

À propos de l'entreprise Pharma Mar, S.A.

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, France, rest of EU, the United States, and internationally. The company operates through Oncology and RNA interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14, which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trial for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trial for treating solid tumors; Tivanisiran, which is in Phase III clinical trial for the treatment of dry eye disease; and SYL1801 that is in phase II clinical trial for treating macular degeneration. In addition, it engages in the development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.